Terms: = Breast cancer AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1 AND Treatment
30 results:
1. Oncolytic Activity of Canine Distemper Virus in Human Ductal breast Carcinoma Cells.
Jhala D; Nathani N; Joshi M; Patel A; Joshi CG
Oncol Res Treat; 2024; 47(1-2):10-17. PubMed ID: 38008084
[TBL] [Abstract] [Full Text] [Related]
2. ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer.
Kim HW; Baek M; Jung S; Jang S; Lee H; Yang SH; Kwak BS; Kim SJ
Epigenetics; 2023 Dec; 18(1):2276384. PubMed ID: 37908128
[TBL] [Abstract] [Full Text] [Related]
3. Echinacoside regulates PI3K/AKT/HIF-1α/VEGF cross signaling axis in proliferation and apoptosis of breast cancer.
Liang H; Yin G; Shi G; Liu Z; Liu X; Li J
Anal Biochem; 2024 Jan; 684():115360. PubMed ID: 37865269
[TBL] [Abstract] [Full Text] [Related]
4. A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells.
Tafti A; Shojaei S; Zali H; Karima S; Mohammadi-Yeganeh S; Mondanizadeh M
Mol Carcinog; 2023 Dec; 62(12):1960-1973. PubMed ID: 37787375
[TBL] [Abstract] [Full Text] [Related]
5. Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y; Katsnelson L; Gritsenko MA; Hu Y; Reva B; Hong R; Wang YT; Kolodziejczak I; Lu RJ; Tsai CF; Bu W; Liu W; Guo X; An E; Arend RC; Bavarva J; Chen L; Chu RK; Czekański A; Davoli T; Demicco EG; DeLair D; Devereaux K; Dhanasekaran SM; Dottino P; Dover B; Fillmore TL; Foxall M; Hermann CE; Hiltke T; Hostetter G; Jędryka M; Jewell SD; Johnson I; Kahn AG; Ku AT; Kumar-Sinha C; Kurzawa P; Lazar AJ; Lazcano R; Lei JT; Li Y; Liao Y; Lih TM; Lin TT; Martignetti JA; Masand RP; Matkowski R; McKerrow W; Mesri M; Monroe ME; Moon J; Moore RJ; Nestor MD; Newton C; Omelchenko T; Omenn GS; Payne SH; Petyuk VA; Robles AI; Rodriguez H; Ruggles KV; Rykunov D; Savage SR; Schepmoes AA; Shi T; Shi Z; Tan J; Taylor M; Thiagarajan M; Wang JM; Weitz KK; Wen B; Williams CM; Wu Y; Wyczalkowski MA; Yi X; Zhang X; Zhao R; Mutch D; Chinnaiyan AM; Smith RD; Nesvizhskii AI; Wang P; Wiznerowicz M; Ding L; Mani DR; Zhang H; Anderson ML; Rodland KD; Zhang B; Liu T; Fenyö D;
Cancer Cell; 2023 Sep; 41(9):1586-1605.e15. PubMed ID: 37567170
[TBL] [Abstract] [Full Text] [Related]
6. PIK3CA and pik3r1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
[TBL] [Abstract] [Full Text] [Related]
7. A novel mutant pik3r1
Wang K; Hu Y; Xu L; Zhao S; Song C; Sun S; Li X; Li M
Mol Biol Rep; 2022 Jul; 49(7):6155-6160. PubMed ID: 35384625
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of the Anticancer Effect of
Nassan MA; Aldhahrani A; Amer HH; Elhenawy A; Swelum AA; Ali OM; Zaki YH
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164019
[TBL] [Abstract] [Full Text] [Related]
9. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
[TBL] [Abstract] [Full Text] [Related]
10. Bio-informatics and in Vitro Experiments Reveal the Mechanism of Schisandrin A Against MDA-MB-231 cells.
Chen L; Ren LQ; Liu Z; Liu X; Tu H; Huang XY
Bioengineered; 2021 Dec; 12(1):7678-7693. PubMed ID: 34550868
[TBL] [Abstract] [Full Text] [Related]
11. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Gris-Oliver A; Ibrahim YH; Rivas MA; García-García C; Sánchez-Guixé M; Ruiz-Pace F; Viaplana C; Pérez-García JM; Llombart-Cussac A; Grueso J; Parés M; Guzmán M; Rodríguez O; Anton P; Cozar P; Calvo MT; Bruna A; Arribas J; Caldas C; Dienstmann R; Nuciforo P; Oliveira M; Cortés J; Serra V
Br J Cancer; 2021 Apr; 124(9):1581-1591. PubMed ID: 33723394
[TBL] [Abstract] [Full Text] [Related]
12. CapG promotes resistance to paclitaxel in breast cancer through transactivation of pik3r1/P50.
Chi Y; Xue J; Huang S; Xiu B; Su Y; Wang W; Guo R; Wang L; Li L; Shao Z; Jin W; Wu Z; Wu J
Theranostics; 2019; 9(23):6840-6855. PubMed ID: 31660072
[No Abstract] [Full Text] [Related]
13. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract] [Full Text] [Related]
14. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract] [Full Text] [Related]
15. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
[TBL] [Abstract] [Full Text] [Related]
16. Effect of
Nassan MA; Soliman MM; Ismail SA; El-Shazly S
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30126855
[TBL] [Abstract] [Full Text] [Related]
17. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract] [Full Text] [Related]
18. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.
Pascual T; Apellániz-Ruiz M; Pernaut C; Cueto-Felgueroso C; Villalba P; Álvarez C; Manso L; Inglada-Pérez L; Robledo M; Rodríguez-Antona C; Ciruelos E
PLoS One; 2017; 12(7):e0180192. PubMed ID: 28727815
[TBL] [Abstract] [Full Text] [Related]
19. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract] [Full Text] [Related]
20. IDH2 Mutations Define a Unique Subtype of breast cancer with Altered Nuclear Polarity.
Chiang S; Weigelt B; Wen HC; Pareja F; Raghavendra A; Martelotto LG; Burke KA; Basili T; Li A; Geyer FC; Piscuoglio S; Ng CK; Jungbluth AA; Balss J; Pusch S; Baker GM; Cole KS; von Deimling A; Batten JM; Marotti JD; Soh HC; McCalip BL; Serrano J; Lim RS; Siziopikou KP; Lu S; Liu X; Hammour T; Brogi E; Snuderl M; Iafrate AJ; Reis-Filho JS; Schnitt SJ
Cancer Res; 2016 Dec; 76(24):7118-7129. PubMed ID: 27913435
[TBL] [Abstract] [Full Text] [Related]
[Next]
